Almost half of the tumours (n = 51, 43.6%) were hormone receptor positive and most patients (n = 88, 75.2%) had a conserved performance status (KPS ≥ 70) at time of BM diagnosis. This evidence concerns the gene NR4A1 and neoplasm.